Opioid Addiction Treatment Co. Nabs $110M For New Product

Law360, New York (January 11, 2018, 6:51 PM EST) -- Braeburn Pharmaceuticals Inc. on Thursday said investors contributed $110 million to a recent funding round as the biotechnology firm targets regulatory approvals and commercialization of the company's latest opioid addiction treatment.

Led by first-time Braeburn investor Wellington Capital Management, the Princeton, New Jersey-based company said it will use the funds from the mezzanine financing round to push forward on obtaining U.S. Food and Drug Administration approval for investigational drug CAM2038 — a weekly or monthly injectable, slow-release product that is intended to treat opioid addiction and chronic pain.

Other first-time investors in Braeburn include Avista Capital Partners, Deerfield Management, New Leaf...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!